TrialStudy of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Trial details
- Registry ID
- NCT07621718
- Phase
- Phase 3
Drug research
Irinotecan
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Camptosar
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )NCT07621718 | RVMD | Phase 3 | Recruiting | 2028-12-30Estimated |
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320 | RVMD | Phase 3 | Active not recruiting | 2026-06Estimated |
| 9-ING-41 in Patients With Advanced CancersNCT03678883 | ACTU | Phase 2 | Active not recruiting | 2026-06Estimated |
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Trial details
- Registry ID
- NCT06625320
- Phase
- Phase 3
9-ING-41 in Patients With Advanced Cancers
Trial details
- Registry ID
- NCT03678883
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |